Grünenthal – pharmaceutical daily

December 3, 2018 Off

AstraZeneca passes prescription medicine rights for Nexium and Vimovo to Grünenthal for $815M

AstraZeneca will divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal for uprfont payments of $815 million.

July 3, 2017 Off

AstraZeneca completes two commercial rights deals, payments included in Q2 2017

By Dino Mustafić

AstraZeneca on Monday reported closing two different agreements for certain commercial rights for its drugs, in Europe and worldwide.

June 7, 2017 Off

Grünenthal buys AstraZeneca’s migraines drug

By Dino Mustafić

AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.